skip to Global Navigation Bar skip to main content

homeHome > About Us > Recruitment > News


News Content
Daewoong Pharmaceutical’s diabetes treatment, ‘DWP16001,’ approved for clinical test phase 2 in Korea.
Date 2019-05-31 Hit 1566
News List
Prev Daewoong Pharmaceutical’s ‘Urusa 300mg’ secured application to ‘prevention of gallbladder stones after gastrectomy’ for the first time in the world.
Next DWN12088, Daewoong Pharmaceutical’s new drug for pulmonary fibrosis, enters global clinical studies phase 1.